Product Images Levetiracetam
View Photos of Packaging, Labels & Appearance
- Label Image - lbl500907770
- Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1
- Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2
- Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3
- Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4
- Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5
- Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6
- Chemical Structure - levetiracetam str
Product Label Images
The following 8 images provide visual information about the product associated with Levetiracetam NDC 50090-7770 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label Image - lbl500907770
Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1
This text includes a figure showing the Responder Rate with a 250% reduction from baseline in Study 1. The data points in the figure range from 0% to 39.6%. The information indicates that the results are statistically significant versus placebo.*
Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2
This text provides a figure showing the Responder Rate (250% Reduction from Baseline) in Study 2, during Period A. The data includes percentages of responder rates for different groups, such as Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. It also indicates a statistically significant result for one of the groups compared to placebo.*
Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3
This text provides data on the Responder Rate (>50% Reduction from Baseline) in Study 3, comparing the results between Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The percentages of responders in each group are shown in a graphical format, with Levetiracetam 3000 mg/day demonstrating a statistically significant difference compared to Placebo.*
Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4
This text provides information about the Responder Rate (a 50% Reduction from Baseline) in Study 4 of a study comparing Placebo (N=97) and Levetiracetam (N=101). The results show that the responder rate was 44.6% for placebo and 45% for Levetiracetam. The text also indicates that Levetiracetam was statistically significant compared to placebo.*
Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5
This data from Figure 5 presents the Responder Rate for all patients aged 1 month to < 4 years, showing a >50% reduction from baseline in Study 5. The result indicates that Lovetracatam had a statistically significant effect compared to placebo, with a response rate of 190.6%.*
Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6
This text provides information on the Responder Rate (250% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7. It includes the percentages of patients responding to treatment with placebo and Levetiracetam, as well as noting a statistically significant difference in effectiveness compared to placebo.*
Chemical Structure - levetiracetam str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
